The global next generation sequencing market is anticipated to reach USD 21.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing coverage of NGS is expected to drive use of precision medicine in oncology from research based setting to clinical cancer setting. Commercial payers are also engaged in reviewing the existing and novel tests in order to establish appropriate medical necessity criteria for their clinical and medical policies.
Moreover, improved understanding of the genetic markers of virulence and resistance provided by next generation sequencing is expected to drive demand of the technology in infectious disease diagnosis.
To request a sample copy or view summary of this report, click the link below:
Further Key Findings from the Report suggest:
Oncology accounted for the dominant share owing to phase-resolved and unambiguous results obtained by using single assay systems, and analysis program.
Targeted resequencing dominated the market owing to its associated benefits such as implementation of the technique such as lower turnaround time and more manageable data sets.
Academic usage of NGS accounted for the largest share with respect to market revenue by end uses and is anticipated to maintain its dominance.
Higher adoption of this technology and platforms in university projects is expected to support the estimated share.
Asia Pacific is estimated to witness the fastest growth over the forecast period owing to expected routing of a considerable portion of whole genome sequencing requirements herein.
Key players operating in the NGS market include Illumina Inc., Agilent Technologies, BGI, Pacific Biosciences, Qiagen, Roche, Thermo Fischer Scientific, and Oxford Nanopore Technologies Ltd.
Endeavors adopted by participants are such as acquisition of Enzymatics by Qiagen acquired solutions in order to enhance the product portfolio with respect to reagents needed in preparatory steps.
Grand View Research has segmented the NGS market on the basis of application, technology, workflow, and end use:
NGS Outlook, by Application (Revenue, USD Million; 2014 - 2025)
HLA Typing/Immune System Monitoring
Metagenomics, Epidemiology & Drug Development
Agrigenomics & Forensics
Non-Communicable / Other Diseases
NGS Outlook, by Technology (Revenue, USD Million; 2014 - 2025)
Targeted Sequencing Analysis
DNA Based Targeted Sequencing Analysis
RNA Based Targeted Sequencing Analysis
Whole Genome Sequencing
Whole Exome Sequencing
NGS Outlook, by Workflow (Revenue, USD Million; 2014 - 2025)
NGS Library Preparation Kits
NGS Semi-automated Library Preparation
NGS Automated Library Preparation
Primary Data Analysis
Secondary Data Analysis
NGS Outlook, by End-use (Revenue, USD Million; 2014 - 2025)
Hospitals & Clinics
Pharma & Biotech Entities
NGS Outlook, by Region (Revenue, USD Million; 2014 - 2025)
Middle East & Africa
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."